Adalimumab, etanercept and ustekinumab for treating plaque psoriasis in children and young people: systematic review and economic evaluation.

BACKGROUND: Psoriasis is a chronic inflammatory disease that predominantly affects the skin. Adalimumab (HUMIRA(®), AbbVie, Maidenhead, UK), etanercept (Enbrel(®), Pfizer, New York, NY, USA) and ustekinumab (STELARA(®), Janssen Biotech, Inc., Titusville, NJ, USA) are the three biological treatments...

Volledige beschrijving

Bewaard in:
Bibliografische gegevens
Gepubliceerd in:Health Technol Assess
Hoofdauteurs: Duarte, Ana, Mebrahtu, Teumzghi, Goncalves, Pedro Saramago, Harden, Melissa, Murphy, Ruth, Palmer, Stephen, Woolacott, Nerys, Rodgers, Mark, Rothery, Claire
Formaat: Artigo
Taal:Inglês
Gepubliceerd in: NIHR Journals Library 2017
Onderwerpen:
Research Article
Online toegang:https://ncbi.nlm.nih.gov/pmc/articles/PMC5694897/
https://ncbi.nlm.nih.gov/pubmed/29105621
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3310/hta21640
Tags: Voeg label toe
Geen labels, Wees de eerste die dit record labelt!

Gelijkaardige items